(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on the decision to raise Gleostine’s price from $50 to $768: “The drug company’s decision to raise the price of the forty-year-old drug Gleostine by 1400% –
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on litigation, filed in the U.S. District Court of the District of Columbia, regarding the Trump administration’s final rule Transparency in Coverage: To avoid higher prescription drug costs for
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Administration’s Executive Order to resurrect the rebate rule. “The Administration’s decision last year to withdraw a proposed regulation on prescription drug
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on President Trump signing into law S. 2553/ S. 2554, the Know the Lowest Price Act of 2018 and the Patient Right to Know Drug Prices Act. “PCMA
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the U.S. House of Representatives’ vote on prescription drug price transparency legislation: “PBMs support increasing transparency across the entire prescription drug supply
“We support (the administration’s) call for greater flexibility in benefit design to encourage better price negotiations…” PCMA said
See Infographic on prescription drug price increases in Medicare Part B
Sanofi and Regeneron have agreed to lower the price of their cholesterol medicine in exchange for easier access for patients covered by pharmacy benefit manager
Three U.S. senators are seeking more information from a Florida company that has steadily increased the price of a 40-year-old cancer drug
©2024 PCMA. All Rights Reserved.
